NCT05844956 - A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG

DZD8586

Daily dose of DZD8586, except for cycle 0 of Part A, in which a single dose of DZD8586 is administrated. Starting dose of DZD8586 is 10 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.

Trial Locations (6)

100142

Research Site, Beijing

100191

Research Site, Beijing

210000

Research Site, Nanjing

310022

Research Site, Hangzhou

450008

Research Site, Zhengzhou

510080

Research Site, Guangzhou